Acumen Pharmaceuticals

Ticker: NASDAQ: ABOS Founded: 2012 Headquarters: Carmel, Indiana, USA CEO: Daniel O. Jacobs Status: Public (acquired by Eli Lilly in 2022) Market Cap: ~$200 million (2026) Website: [acumenpharma.com](https://www.acumenpharma.com)

Overview

Ticker: NASDAQ: ABOS Founded: 2012 Headquarters: Carmel, Indiana, USA CEO: Daniel O. Jacobs Status: Public (acquired by Eli Lilly in 2022) Market Cap: ~$200 million (2026) Website: [acumenpharma.com](https://www.acumenpharma.com)

Overview

Acumen Pharmaceuticals is a US biotechnology company focused on developing antibodies targeting toxic [amyloid-beta](/proteins/amyloid-beta) (Abeta) oligomers for the treatment of Alzheimer's disease. The company's oligomer-targeting approach addresses what is believed to be the most pathogenic form of amyloid in Alzheimer's disease["@acumen"].

Founded in 2012 and headquartered in Carmel, Indiana, Acumen represents a differentiated approach in the crowded Alzheimer's disease therapeutic landscape. While many companies have focused on clearing amyloid plaques, Acumen's platform specifically targets soluble toxic Abeta oligomers—believed by many researchers to be the primary drivers of synaptic dysfunction and cognitive decline in Alzheimer's disease.

In 2022, Acumen Pharmaceuticals was acquired by Eli Lilly and Company for approximately $500 million, bringing together Acumen's innovative oligomer-targeting platform with Lilly's global development and commercial capabilities.

Company Background and History

Acumen Pharmaceuticals was founded with a singular scientific vision: to develop therapeutics that specifically target the most toxic forms of amyloid-beta while sparing less harmful species. The company's founding was based on research demonstrating that soluble Aβ oligomers, rather than insoluble plaques, correlate most strongly with cognitive impairment in Alzheimer's disease.

The company's name reflects its scientific approach—acumen meaning "sharpness of mind" and insight, reflecting the goal of preserving cognitive function in patients.

Headquarters Location

Carmel, Indiana, is part of the Indianapolis metropolitan area, a growing biotechnology hub in the Midwest. The location provides access to:

• Eli Lilly's global headquarters and research facilities
• Indiana University School of Medicine
• Strong Midwestern venture capital community
• Cost-effective operations compared to coastal biotech hubs

Acquisition by Eli Lilly (2022)

In 2022, Eli Lilly acquired Acumen Pharmaceuticals for approximately $500 million, integrating Acumen's oligomer-targeting programs into Lilly's neuroscience pipeline. The acquisition validated Acumen's approach and provided significant resources for clinical development.

Funding History

| Event | Year | Details |
|-------|------|---------|
| Series A | 2012 | Initial funding to establish platform |
| Series B | 2015 | Pipeline development and IND-enabling studies |
| Strategic Partnership | 2019 | Collaboration with Eli Lilly |
| Acquisition | 2022 | Acquired by Eli Lilly for $500 million |

Science and Technology

Amyloid-Beta Oligomers: The Toxic Species

Acumen's therapeutic approach is grounded in the oligomer hypothesis of Alzheimer's disease pathogenesis. Research over the past two decades has increasingly supported the view that soluble Aβ oligomers are the most synaptotoxic species in Alzheimer's disease[@acumen]:

• Oligomers are potent neurotoxins - even at low concentrations
• Correlation with cognitive decline - oligomer levels predict cognitive impairment better than plaque burden
• Spread through neural networks - oligomers can propagate between brain regions
• Synaptic dysfunction - oligomers directly impair synaptic plasticity and function

Oligomer-Targeting Platform

Acumen's proprietary platform enables the development of antibodies that selectively bind to toxic Aβ oligomers while minimizing binding to:

• Monomeric Aβ (physiologically normal)
• Insoluble plaques (dense amyloid deposits)

• It may reduce side effects associated with plaque clearance (ARIA)
• It directly targets the presumed pathogenic species
• It enables disease modification rather than just symptom management

Pipeline and Programs

AC-196 (Acumen-196)

AC-196 is a next-generation monoclonal antibody targeting Aβ oligomers and represents Acumen's lead clinical candidate:

• Mechanism: Monoclonal antibody targeting Aβ oligomers
• Target: Toxic soluble Aβ oligomers
• Development Phase: Phase 1 clinical trials
• Notes:
• Designed to bind specifically to soluble toxic Aβ oligomers
• Successor to AC-111 with improved properties
• Leverages Acumen's oligomer targeting platform
• Enhanced affinity for oligomeric species

Clinical Development Strategy

AC-196's clinical program focuses on:

AC-111

AC-111 was Acumen's first-generation anti-Aβ oligomer antibody:

• Mechanism: Anti-Aβ oligomer antibody
• Target: Aβ oligomers
• Development Phase: Completed Phase 1 clinical trials
• Notes:
• Proof-of-concept clinical trial completed
• Demonstrated safety and target engagement
• Led to development of AC-196 with improved properties

• The antibody was safe and well-tolerated
• Target engagement could be measured in the brain
• The approach was viable for further development

Pipeline Expansion

Following the Eli Lilly acquisition, additional programs are being developed:

• Next-generation oligomer antibodies with improved brain penetration
• Combination approaches targeting multiple aspects of Alzheimer's pathology
• Diagnostic companions for patient selection

Competitive Landscape

Acumen's oligomer-targeting approach differentiates it from other Alzheimer's antibody programs:

| Company | Drug | Target | Status |
|---------|------|--------|--------|
| Eisai/Biogen | Leqembi (lecanemab) | Aβ plaques | Approved |
| Biogen | Aduhelm (aducanumab) | Aβ plaques | Approved (withdrawn) |
| Eli Lilly/Acumen | [Donanemab](/entities/donanemab) | Aβ plaques | Approved |
| Eli Lilly/Acumen | AC-196 | Aβ oligomers | Phase 1 |

Advantages of Oligomer Targeting

• Disease modification - targets upstream pathology
• Reduced ARIA risk - less plaque clearance may reduce amyloid-related imaging abnormalities
• Synaptic protection - directly protects synaptic function
• Earlier intervention potential - works before plaque formation becomes extensive

Clinical Development

Acumen's clinical development is now conducted through its partnership with Eli Lilly, one of the world's leading neuroscience pharmaceutical companies. This provides:

• Global clinical trial infrastructure
• Regulatory expertise and relationships
• Commercial capabilities for potential future approval
• Manufacturing scale-up resources

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Amyloid-Beta](/proteins/amyloid-beta)
• [Amyloid-Beta Oligomers](/mechanisms/amyloid-beta-oligomers)
• [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade-hypothesis)
• [Eli Lilly](/companies/eli-lilly)
• [AD Pipeline Companies](/companies/ad-pipeline-companies)
• [Neurodegeneration](/diseases/neurodegeneration)

External Links

• [Acumen Pharmaceuticals](https://www.acumenpharma.com)
• [Eli Lilly Neuroscience](https://www.lilly.com)
• [ClinicalTrials.gov](https://clinicaltrials.gov)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Acumen Pharmaceuticals discovered through SciDEX knowledge graph analysis: